REGN2477

Phase 2Small molecule

REGN2477 is one of 50 small molecule programs targeting Fibrodysplasia Ossificans Progressiva. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Fibrodysplasia Ossificans ProgressivaActive, not recruiting

Obsessive-Compulsive DisorderActive, not recruiting

Fibrodysplasia Ossificans ProgressivaPhase 2

Active, not recruiting

Obsessive-Compulsive DisorderPhase 2

Active, not recruiting

Competition

Competitive Landscape

56 competitors in Obsessive-Compulsive Disorder

#DrugCompanyPhaseTrials

Lexapro

AbbVie

Approved

6 2

Ingrezza

Neurocrine Biosciences

Approved

1 3

Celexa

Revia

Prozac

VVitae Pharmaceuticals Inc., an Allergan affiliate

Approved

4 6

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Approved

4 7

Zoloft

VViatris Specialty LLC

Approved

3 8

Tasmar

BBausch Health Americas, Inc.

Approved

2 9

Topamax

WWim Janssens

Approved

2 10

Paxil

SSebela Pharmaceuticals Development LLC

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Single Ascending Dose1 trial

A Study to Examine the Safety and Tolerability of Single Ascending Doses of REGN2477

Completed· Regeneron logo

Regeneron·Phase 1·NCT02870400·41 enrolled

Postmenopausal Women1 trial

Study of Safety, Tolerability, and Pharmacokinetics of REGN2477 Alone and in Combination With REGN1033 in Healthy Postmenopausal Women and Healthy Adult Men

Completed· Regeneron logo

Regeneron·Phase 1·NCT02943239·82 enrolled

Fibrodysplasia Ossificans Progressiva1 trial

A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva

Completed· Regeneron logo

Regeneron·Phase 2·NCT03188666·44 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for REGN2477. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — REGN2477 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for REGN2477. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Regeneron company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Regeneron

REGN2477

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Single Ascending Dose1 trial

Postmenopausal Women1 trial

Fibrodysplasia Ossificans Progressiva1 trial

References

Drug Info

Quick Facts

Related News